Summary
The beta-adrenoceptor blocking activity of the new Class Ic-antiarrhythmic drug diprafenone has been determined in man in comparison with that of propranolol, using the standardized isoproterenol test.
Following placebo, the dose of isoproterenol which increased the heart rate by 25 beats·min−1 (CD25) was 0.84 (0.1–2.72) µg (median and range). Two hours following single oral doses of 200 mg diprafenone (3.61 µg; 1.53–44.15) or 40 mg propranolol (16.06 µg; 9.15–27.04) significantly higher CD25-values were found. The affinity constants for the beta-adrenergic receptors calculated on the basis of free drug in the plasma were similar for propranolol and diprafenone (2.79 vs. 2.60 nM−1, respectively).
Thus, diprafenone showed a definite degree of beta-blocking activity in a clinically relevant range of plasma concentrations.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Heuer H, Gülker H, Thale J, Olbing B (1984) Experimentelle und klinische elektrophysiologische Befunde zur Wirkung von Diprafenon. Z Kardiol 73 [Suppl]: 46 (abstract)
Heuer H, Gülker H, Müller US, Bender F (1985) Elektrophysiologische und antiarrhythmische Wirkungen von Diprafenon. Z Kardiol 74 [Suppl]: 89 (abstract)
Heuer H, Gülker H, Hasfeld M, Pook U, Bender F (1986) Langzeittherapie mit dem neuen Antiarrhythmikum Diprafenon. Z Kardiol 75 [Suppl]: 101 (abstract)
Manz M, Beermann J, Gerckens U, Lüderitz B (1986) Elektrophysiologische Wirkungen von Diprafenon bei supraventrikulärer und ventrikulärer Tachykadie. Z Kardiol 75: 757–763
Heuer H, Gülker H, Hasfeld M, Frenking B, Behrenbeck T (1987) Behandlung chronischer ventrikulärer Arrhythmien mit dem neuen Klasse-Ic-Antiarrhythmikum Diprafenon — Ergebnisse der Langzeittherapie. Z Kardiol 76: 415–420
McLeod AA, Stiles GL, Shand DG (1984) Demonstration of beta-adrenoceptor blockade by propafenone hydrochloride: Clinical pharmacologic, radioligand binding and adenylate cyclase activation studies. J Pharmacol Exp Ther 228: 461–466
Gülker H, Heuer H, Thale J, Behrenbeck T (1987) Elektrophysiologische und hämodynamische Wirkungen der neuen antiarrhythmischen Substanz Diprafenon. Z Kardiol 76: 411–414
Gülker H, Thale J, Olbing B, Heuer H, Frenking B, Bender F (1985) Assessment of the antiarrhythmic profile of the new Class I agent diprafenone. Arzneimittelforsch/Drug Res 35: 1387–1393
Cleaveland CR, Rangno RE, Shand DG (1972) A standardized isoproterenol sensitivity test. Arch Intern Med 130: 47–52
McDevitt DG, Frisk-Holmberg M, Hollifield JW, Shand D (1976) Plasma binding and the affinity of propranolol for a beta receptor in man. Clin Pharmacol Ther 20: 152–157
Pritchard JF, Schneck DW, Hayes AH (1979) Determination of propranolol and six metabolites in human urine by high-pressure liquid chromatography. J Chromatogr 162: 47–58
Schmidt W, Jähnchen E (1979) Interaction of phenylbutazone with racemic phenprocoumon and its enantiomers in rats. J Pharmacokinet Biopharm 7: 643–663
Holford NHG, Sheiner LB (1981) Understanding the dose-effect relationship: Clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 6: 429–453
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wagner, F., Jähnchen, E. & Trenk, D. Evaluation of the beta-adrenoceptor blocking activity of the Class Ic antiarrhythmic drug diprafenone in man. Eur J Clin Pharmacol 36, 579–582 (1989). https://doi.org/10.1007/BF00637739
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00637739